secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0001641172-25-000693
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine initiates Phase 3 outpatient PPD trial of LPCN 1154; dosing expected Q2 2025
--------------------------------------------------------------------------------

- Initiation of randomized, blinded, placebo-controlled Phase 3 trial of LPCN 1154 for PPD; first patient dosing expected Q2 2025.
- 48-hour at-home self-administration regimen based on FDA protocol feedback.
- Primary endpoint: change from baseline in HAM-D; secondary endpoints include MADRS and HAM-A.
- Trial size powered based on observed effect of injectable brexanolone (Zulresso).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000164117225000693/0001641172-25-000693-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000164117225000693/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000693

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer